According to APASAL and AASLD guidelines [26,27], in patients with advanced liver fibrosis, HCV NS3/4A inhibitors, such as GLE/PIB, should be avoided due to the risk of liver decompensation during the treatment. This evidence concerns the gene KRAS and Hepatic fibrosis.